Skip to main content

Viatris Inc statistics

  • VTRS · Nasdaq
  • Pharmaceuticals
  • S&P 500
$20.82+0.73%Close 13 Nov 2026

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Enterprise value$35.66B
EV / EBITDA12.70
EV / sales2.42

Share price

Latest close$20.82
Day's change+0.7%
52-week high$21.20
52-week low$10.15
From 52-week high−1.8%
Return · 1 month+11.6%
Return · 3 months+29.2%
Return · year to date+67.2%
Return · 1 year+89.1%
Beta · 1 year against the S&P 5000.64
50-day average$18.11
200-day average$16.24
RSI 1470.1
Average volume · 20 sessions9.6M

Margins and returns

For fiscal 2025, as filed.

Gross margin35.1%
Operating margin−18.6%
Net margin−24.6%
Free cash flow margin13.5%
Return on equity−21.1%
Return on assets−5.3%
Return on invested capital−6.4%
Return on capital employed−8.1%
Stock-based compensation / revenue1.2%

Financial position

At the end of fiscal 2025.

Cash and equivalents$1.32B
Total debt$14.70B
Net debt$13.34B
Current ratio1.38
Debt / equity1.00
Net debt / EBITDA98.66
Interest coverage−5.65

Shares and dividends

For fiscal 2025, as filed.

Diluted shares1.2B
Net share repurchases$497.9M
Dividends per share$0.48

Taxes

For fiscal 2025, as filed.

Income tax expense−$150.1M
Effective tax rate4.1%

VTRS in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.